Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Verizon Communications Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.5 (market cap $39.89B), while Verizon Communications Inc trades at $42.73 (market cap $175.87B). The key difference: Verizon Communications Inc is far larger — about 4.4× Alnylam Pharmaceuticals, Inc.'s market cap, and Verizon Communications Inc pays a 6.72% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | VZ | |
|---|---|---|
Market Cap | $39.89B | $175.87B |
Sector | Health | Media |
52-Week High | $491.22 | $51.38 |
52-Week Low | $278.09 | $38.40 |
Enterprise Value | $38.15B | $363.38B |
Volume | — | 22,584,735 |
Dividend Yield | — | 6.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Verizon (VZ) trades at $42.12, down 0.28% today, with a bearish technical signal but strong fundamentals including a P/E of 10.27 and consistent earnings beats. Recent news highlights include a new BMW connectivity partnership and inclusion in high-yield dividend stock lists. Cash flow improved significantly in 2025 with net cash flow of $14.9 billion, though long-term debt remains elevated at $121.38 billion.
Outlook: VZ offers value with a 6.7% dividend yield and analyst consensus price target of $48.17 (14% upside). Risks include competitive pressure from SpaceX's Starlink and high debt load. The stock is a buy for income investors seeking stability, but growth may be limited by industry saturation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
